



# SAFETY DATA SHEET

Date of Preparation: 9/9/14

Page 2 of 2

3550300

Section 8 continued

N/E: Not Established

**ENGINEERING CONTROLS:** Use with adequate ventilation. Use explosion-proof equipment.

**PERSONAL PROTECTIVE EQUIPMENT:** Safety glasses, chemical-resistant gloves.

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

**BOILING POINT:** 322 degrees F

**VAPOR DENSITY:** >1 (air=1)

**% VOLATILE BY VOLUME:** N/E

**EVAPORATION RATE:** <1 (Ether=1)

**pH LEVEL:** N/E

**% VOLATILE BY WEIGHT:** 70 (approximate)

**WEIGHT PER GALLON:** 7.80

**PRODUCT APPEARANCE:** Clear Liquid

**VOC CONTENT:** 653 g/L

## SECTION 10: STABILITY/REACTIVITY

**STABILITY:** Stable.

**HAZARDOUS POLYMERIZATION:** Will not occur.

**CONDITIONS AND MATERIALS TO AVOID:** Oxidizing agents, strong acids, and strong alkalis.

**HAZARDOUS DECOMPOSITION PRODUCTS:** Carbon monoxide, carbon dioxide, and incomplete combustion products.

## SECTION 11: TOXICOLOGICAL INFORMATION

**EYE CONTACT:** Direct contact may cause mild to moderate irritation. Product vapors/mists may also cause irritation.

**SKIN CONTACT:** Direct contact may cause slight skin irritation. Prolonged/repeated contact may result in irritation/dermatitis.

**INHALATION:** Exposure may cause irritation of the nose, throat, respiratory tract, and other mucous membranes. Exposure to excessive vapor concentrations may cause signs of transient central nervous system depression (headache, fatigue, drowsiness, dizziness, loss of coordination.)

**INGESTION:** May result in irritation of the gastrointestinal tract. Ingestion of excessive quantities may result in symptoms of transient central nervous system depression as noted above.

**SIGNS AND SYMPTOMS:** Symptoms of eye irritation include tearing, reddening, and swelling. Symptoms of skin irritation include redness and swelling. Gastrointestinal irritation symptoms include nausea, vomiting, and abdominal discomfort. Symptoms of respiratory irritation include runny nose, sore throat, coughing, chest discomfort, shortness of breath, and reduced lung function.

Symptoms of transient central nervous system depression include headache, fatigue, drowsiness, dizziness, and loss of coordination.

**AGGRAVATED MEDICAL CONDITIONS:** Pre-existing skin, eye, and respiratory disorders may be aggravated by exposure to this product.

**OTHER HEALTH EFFECTS:** Ethylene Glycol Monobutyl Ether has been shown to cause the following effects in laboratory animals: mild reversible liver/kidney effects, blood abnormalities, cancer, and harm to the fetus. The relevance to humans is uncertain.

## SECTION 12: ECOLOGICAL INFORMATION

**ECOTOXICITY:** N/E

**DEGRADABILITY:** N/E

**BIOACCUMULATIVE POTENTIAL:** N/E

**SOIL MOBILITY:** N/E

**OTHER ADVERSE EFFECTS:** None Recognized

## SECTION 13: WASTE DISPOSAL INFORMATION

**WASTE DISPOSAL INFORMATION:** Fuel blending at a permitted waste disposal facility. Product is a hazardous waste.

## SECTION 14: TRANSPORTATION INFORMATION

**HAZARDOUS/NON-HAZARDOUS MATERIAL:** Not regulated by DOT. (Domestic Land Transportation)

**UN NUMBER:** None.

**HAZARD CLASS:** N/A

**PACKING GROUP:** N/A

**UN PROPER SHIPPING NAME:** N/A

**ENVIRONMENTAL HAZARDS:** None recognized.

**BULK TRANSPORTATION INFORMATION:** None.

**SPECIAL PRECAUTIONS:** None.

## SECTION 15: REGULATORY INFORMATION

**OTHER REGULATORY CONSIDERATIONS:** None recognized.

## SECTION 16: OTHER INFORMATION

**PREPARATION DATE:** 9/9/2014

**PREPARED BY:** Dave Carey

The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of this product described herein.